Forster M - Search Results

1

Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK.

Forster M, Liang XJ, Schröder M, Gerstenecker S, Chaikuad A, Knapp S, Laufer S, Gehringer M. Forster M, et al. Int J Mol Sci. 2020 Dec 4;21(23):9269. doi: 10.3390/ijms21239269. Int J Mol Sci. 2020. PMID: 33291717 Free PMC article.

2

Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket.

Forster M, Chaikuad A, Bauer SM, Holstein J, Robers MB, Corona CR, Gehringer M, Pfaffenrot E, Ghoreschi K, Knapp S, Laufer SA. Forster M, et al. Cell Chem Biol. 2016 Nov 17;23(11):1335-1340. doi: 10.1016/j.chembiol.2016.10.008. Epub 2016 Nov 10. Cell Chem Biol. 2016. PMID: 27840070 Free PMC article.

3

Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4- d]pyrrolo[2,3- b]pyridine Scaffold.

Forster M, Chaikuad A, Dimitrov T, Döring E, Holstein J, Berger BT, Gehringer M, Ghoreschi K, Müller S, Knapp S, Laufer SA. Forster M, et al. J Med Chem. 2018 Jun 28;61(12):5350-5366. doi: 10.1021/acs.jmedchem.8b00571. Epub 2018 Jun 13. J Med Chem. 2018. PMID: 29852068

4

Fast Iterative Synthetic Approach toward Identification of Novel Highly Selective p38 MAP Kinase Inhibitors.

Röhm S, Berger BT, Schröder M, Chaikuad A, Winkel R, Hekking KFW, Benningshof JJC, Müller G, Tesch R, Kudolo M, Forster M, Laufer S, Knapp S. Röhm S, et al. Among authors: forster m. J Med Chem. 2019 Dec 12;62(23):10757-10782. doi: 10.1021/acs.jmedchem.9b01227. Epub 2019 Nov 26. J Med Chem. 2019. PMID: 31702918

5

Novel hinge-binding motifs for Janus kinase 3 inhibitors: a comprehensive structure-activity relationship study on tofacitinib bioisosteres.

Gehringer M, Forster M, Pfaffenrot E, Bauer SM, Laufer SA. Gehringer M, et al. Among authors: forster m. ChemMedChem. 2014 Nov;9(11):2516-27. doi: 10.1002/cmdc.201402252. Epub 2014 Aug 19. ChemMedChem. 2014. PMID: 25139757

6

Solution-phase parallel synthesis of ruxolitinib-derived Janus kinase inhibitors via copper-catalyzed azide-alkyne cycloaddition.

Gehringer M, Forster M, Laufer SA. Gehringer M, et al. Among authors: forster m. ACS Comb Sci. 2015 Jan 12;17(1):5-10. doi: 10.1021/co500122h. Epub 2014 Dec 1. ACS Comb Sci. 2015. PMID: 25405713

7

Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting.

Forster M, Gehringer M, Laufer SA. Forster M, et al. Bioorg Med Chem Lett. 2017 Sep 15;27(18):4229-4237. doi: 10.1016/j.bmcl.2017.07.079. Epub 2017 Jul 29. Bioorg Med Chem Lett. 2017. PMID: 28844493 Review.

8

An updated patent review of p38 MAP kinase inhibitors (2014-2019).

Haller V, Nahidino P, Forster M, Laufer SA. Haller V, et al. Among authors: forster m. Expert Opin Ther Pat. 2020 Jun;30(6):453-466. doi: 10.1080/13543776.2020.1749263. Epub 2020 Apr 20. Expert Opin Ther Pat. 2020. PMID: 32228113 Review.

9

Bioisosteric Replacement of Arylamide-Linked Spine Residues with N-Acylhydrazones and Selenophenes as a Design Strategy to Novel Dibenzosuberone Derivatives as Type I 1/2 p38α MAP Kinase Inhibitors.

Pedreira JGB, Nahidino P, Kudolo M, Pantsar T, Berger BT, Forster M, Knapp S, Laufer S, Barreiro EJ. Pedreira JGB, et al. Among authors: forster m. J Med Chem. 2020 Jul 9;63(13):7347-7354. doi: 10.1021/acs.jmedchem.0c00508. Epub 2020 Jun 11. J Med Chem. 2020. PMID: 32462866

10

Decisive role of water and protein dynamics in residence time of p38α MAP kinase inhibitors.

Pantsar T, Kaiser PD, Kudolo M, Forster M, Rothbauer U, Laufer SA. Pantsar T, et al. Among authors: forster m. Nat Commun. 2022 Jan 28;13(1):569. doi: 10.1038/s41467-022-28164-4. Nat Commun. 2022. PMID: 35091547 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

990 results

Search Page